Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study.

[1]  D. Sanders,et al.  Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. , 2015, The Journal of pediatrics.

[2]  S. Stick,et al.  Biomarkers in Paediatric Cystic Fibrosis Lung Disease. , 2015, Paediatric respiratory reviews.

[3]  F. Gottrand,et al.  Impact of fish oils on the outcomes of a mouse model of acute Pseudomonas aeruginosa pulmonary infection. , 2015, The British journal of nutrition.

[4]  F. Huaux,et al.  Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. , 2014, Clinical biochemistry.

[5]  J. Roca‐Ferrer,et al.  Quantification of major urinary metabolites of PGE2 and PGD2 in cystic fibrosis: correlation with disease severity. , 2013, Prostaglandins, leukotrienes, and essential fatty acids.

[6]  S. Quattrucci,et al.  Clinical effects of diet supplementation with DHA in pediatric patients suffering from cystic fibrosis. , 2013, Minerva pediatrica.

[7]  C. Agostoni,et al.  A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis. , 2013, Prostaglandins, Leukotrienes and Essential Fatty Acids.

[8]  B. Strandvik,et al.  Relation Between Dietary Fat Intake Type and Serum Fatty Acid Status in Children With Cystic Fibrosis , 2012, Journal of pediatric gastroenterology and nutrition.

[9]  M. Laposata,et al.  DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity , 2012, Journal of Lipid Research.

[10]  J. Rodríguez-soriano,et al.  Persistence of Essential Fatty Acid Deficiency in Cystic Fibrosis Despite Nutritional Therapy , 2009, Pediatric Research.

[11]  R. Chiron,et al.  Lipoxin A(4) and interleukin-8 levels in cystic fibrosis sputum after antibiotherapy. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[12]  A. Christophe,et al.  Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. , 2008, Prostaglandins, leukotrienes, and essential fatty acids.

[13]  M. Konstan,et al.  Sputum biomarkers of inflammation in cystic fibrosis lung disease. , 2007, Proceedings of the American Thoracic Society.

[14]  D. Ma,et al.  Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. , 2006, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[15]  M. Regan,et al.  Association of cystic fibrosis with abnormalities in fatty acid metabolism. , 2004, The New England journal of medicine.

[16]  R. Gibson,et al.  Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[17]  S. Freedman,et al.  A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Frascarolo,et al.  Essential fatty acid deficiency in well nourished young cystic fibrosis patients , 1997, European Journal of Pediatrics.

[19]  L. J. Baer,et al.  The absorption and effect of dietary supplementation with omega‐3 fatty acids on serum leukotriene B4, in patients with cystic fibrosis , 1994, Pediatric pulmonology.

[20]  W. Henderson,et al.  Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. , 1994, The Journal of pediatrics.

[21]  E. Schaefer,et al.  Criteria for essential fatty acid deficiency in plasma as assessed by capillary column gas-liquid chromatography. , 1987, Clinical chemistry.

[22]  S. Freedman,et al.  Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. , 2007, Clinical chemistry.

[23]  J. Lloyd-Still,et al.  Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. , 2006, Nutrition.

[24]  F. De Baets,et al.  Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis. , 1992, Annals of nutrition & metabolism.